1. Home
  2. XFOR vs ABVE Comparison

XFOR vs ABVE Comparison

Compare XFOR & ABVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XFOR
  • ABVE
  • Stock Information
  • Founded
  • XFOR 2014
  • ABVE 2019
  • Country
  • XFOR United States
  • ABVE Canada
  • Employees
  • XFOR N/A
  • ABVE N/A
  • Industry
  • XFOR Biotechnology: Biological Products (No Diagnostic Substances)
  • ABVE Packaged Foods
  • Sector
  • XFOR Health Care
  • ABVE Consumer Staples
  • Exchange
  • XFOR Nasdaq
  • ABVE Nasdaq
  • Market Cap
  • XFOR 84.3M
  • ABVE 90.1M
  • IPO Year
  • XFOR N/A
  • ABVE N/A
  • Fundamental
  • Price
  • XFOR $3.21
  • ABVE $1.57
  • Analyst Decision
  • XFOR Strong Buy
  • ABVE
  • Analyst Count
  • XFOR 3
  • ABVE 0
  • Target Price
  • XFOR $34.17
  • ABVE N/A
  • AVG Volume (30 Days)
  • XFOR 1.5M
  • ABVE 1.7M
  • Earning Date
  • XFOR 11-12-2025
  • ABVE 01-01-0001
  • Dividend Yield
  • XFOR N/A
  • ABVE N/A
  • EPS Growth
  • XFOR N/A
  • ABVE N/A
  • EPS
  • XFOR N/A
  • ABVE N/A
  • Revenue
  • XFOR $32,774,000.00
  • ABVE $213,446,206.00
  • Revenue This Year
  • XFOR $1,313.84
  • ABVE N/A
  • Revenue Next Year
  • XFOR N/A
  • ABVE N/A
  • P/E Ratio
  • XFOR N/A
  • ABVE N/A
  • Revenue Growth
  • XFOR 5721.31
  • ABVE N/A
  • 52 Week Low
  • XFOR $1.35
  • ABVE $0.25
  • 52 Week High
  • XFOR $26.83
  • ABVE $4.40
  • Technical
  • Relative Strength Index (RSI)
  • XFOR 51.32
  • ABVE 41.21
  • Support Level
  • XFOR $3.08
  • ABVE $1.61
  • Resistance Level
  • XFOR $3.79
  • ABVE $1.70
  • Average True Range (ATR)
  • XFOR 0.40
  • ABVE 0.12
  • MACD
  • XFOR -0.11
  • ABVE -0.03
  • Stochastic Oscillator
  • XFOR 16.92
  • ABVE 14.72

About XFOR X4 Pharmaceuticals Inc.

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

About ABVE Above Food Ingredients Inc. Common Stock

Above Food Ingredients Inc is a differentiated, regenerative ingredient company. Its products are made with real nutritious, flavorful ingredients and delivered with transparency. Its vision is to create a healthier world one seed, one field, and one bite at a time. With a robust chain of custody of plant proteins, enabled by scaled operations and infrastructure in primary agriculture and processing, and proprietary seed development capabilities that leverage the power of artificial intelligence driven genomics. The company delivers nutritious foods to businesses and consumers with traceability and sustainability. Above Food's consumer products and brands are available in grocers across Canada and the United States.

Share on Social Networks: